Scinai Immunotherapeutics LT
13F holders, Q2 2024 (June 30)9holders
$2.78avg. 13F price*
At the end of Q2 2024, 9 institutions reported holding Scinai Immunotherapeutics LT in their 13F filings. The largest holders were Sabby Management, LLC ($50K), Rhumbline Advisers ($3K) and Morgan Stanley ($709).
- Company
- Scinai Immunotherapeutics LT
- Filed as
- BIONDVAX PHARMACEUTICALS LTD (Q2 2024)
- CUSIP
- 09073Q303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $278 |
| Exits | 0 | $0 |
Ownership 9 holders
| Sabby Management, LLC | 0.74% | Reduce -29.6% | 17,828 | $50K |
| Rhumbline Advisers | 0.00% | Add +71.0% | 1,138 | $3K |
| Morgan Stanley | 0.00% | Reduce -1.1% | 255 | $709 |
| UBS Group AG | 0.00% | Reduce -0.4% | 211 | $586 |
| Bank of America Corp. | 0.00% | New | 100 | $278 |
| Credit Agricole S A | 0.00% | Reduce -0.9% | 42 | $117 |
| Aspire Private Capital, LLC | 0.00% | Add +100.0% | 32 | $89 |
| Main Street Group, LTD | 0.00% | No change | 20 | $59 |
| Global Retirement Partners, LLC | 0.00% | No change | 5 | $14 |
"% of holder's portfolio" is SCINAI IMMUNOTHERAPEUTICS LT's weight in each manager's 13F, not the share of Scinai Immunotherapeutics LT the manager owns.